The first ophthalmologic biosimilar did not launch in the U.S. until July 2022, and some prescribers are still cautious about their uses, according to Cardinal Health’s 2023 “Biosimilars Report,” which surveyed over 350 providers in four physician specialties.
How ophthalmologists feel about biosimilars
